Abstract: A recombinant protein is provided containing a serum albumin multimer wherein at least two genes encoding serum albumin are combined with each other by gene recombinant technology and incorporated into a host cell for the effective production of the protein. The gene encoding a human serum albumin multimer and the recombinant vector are also provided. The protein is used as a safe drug administration carrier that is capable of extending the half life of a drug in the blood without the risk of contamination of viruses and so on, as compared with a conventional drug administration carrier.

Abstract: To provide a transmucous absorption enhancer comprising a medium-chain fatty acid salts or a bile acid salt and a glycyrrhizic acid salts capable of sustaining the effect of the absorption enhancer and allowing an agent (especially a physiologically active peptide) to be absorbed via a mucosa (especially a large intestine mucosa).

Abstract: The present invention relates to a drug composition in which the solubility and the dissolution rate of a drug having low water solubility are improved by incoroprating therein a low molecular weight chitosan in an amount of from 0.2 to 10 parts by weight per one part by weight of the poorly water-soluble drug. As the low molecular weight chitosan, those having a weight average molecular weight in the range from 500 to 50,000 and soluble in water were employed. This drug composition is prepared by mixing the components intimately so as to obtain a homogeneous dispersion of the low molecular weight chitosan with the mass of the composition.The drug composition according to the invention can be worked up into various preparation forms, such as, granules etc., as medicaments for administration to living organisms in which the bioabsorptivity and biouptake are improved.

Abstract: 2-Substituted-N-{3-[3-(1-piperidinomethyl)phenoxy]propyl}acetamide, derivatives thereof, and pharmaceutically acceptable salts thereof. The substitution group may be aminomethylcyclohexane carbonyl group or N-carbobenzoxy-p-aminomethylhexane carbonyl group. The compounds having the first-mentioned group can be an effective component of an antiulcer drug composition, and the compounds of the last-mentioned group are intermediates for producing the compounds having the first-mentioned group. Disclosed also is an antiulcer drug composition comprising the above compound as an effective component. The antiulcer drug composition exhibits both the gastric acid secretion inhibitive activity and the gastric mucosa protective activity, and is effective as suppression and cure of ulcers.

Abstract: A slow-releasing pharmaceutical easily prepared with alginic acid gel beads as a slow releasing carrier, and a basic medicament such as a beta-blocking agent or a calcium antagonistic agent therein, whereby the basic medicament can be relesed at a desired rate by means of oral administration, etc.

Abstract: Pharmaceutical preparations for oral administration are disclosed which comprise (a) an acidic non-steroidal anti-inflammatory agent having the mean particle size of about 100 .mu.m or less and (b) a protein hydrolyzate or a polypeptide having the mean molecular weight of 4000-12000. The pharmaceutical preparations are in the form of tablets, granules, capsules and dry syrups. They achieve high bioavailability of the anti-inflammatory agent, e.g., ibuprofen.